Navigation Links
Versus Technology Announces Fourth Quarter Results
Date:12/28/2007

ended October 31, 2007 and 2006, have been prepared by management.

Management has elected to omit substantially all of the footnote disclosures required by accounting principles generally accepted in the United States. If the omitted disclosures were included in the financial statements, they might influence the user's conclusions about the Company's financial position, results of operations, and cash flows. Accordingly, these financial statements are not designed for those who are not informed about such matters.

The reader should refer to the Versus Technology, Inc. 2006 Annual Report which is available at http://www.versustech.com/annual_reports.htm for further details regarding the 2006 results. The full annual report for 2007 will be published at http://www.versustech.com when available.

Richard W. Ebersole

Chief Financial Officer

December 28, 2007

VERSUS TECHNOLOGY, INC. AND SUBSIDIARY

Consolidated Balance Sheets

October 31, 2007 and 2006

October 31,

2007 2006

Assets

Current Assets

Cash and cash equivalents $ 2,428,000 $ 1,401,000

Accounts receivable, including

$91,000 and $23,000 of unbilled

revenues 1,134,000 1,714,000

Inventories 824,000 576,000

Prepaid expenses and other current

assets 127,000 62,000

Total Current Assets 4,513,000 3,753,000

Property and Equipment

Machinery and equipment 374,000
'/>"/>

SOURCE Versus Technology, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Quantum light beams good for fast technology
2. New Smart Technology Makes Patient Data Collection Easier, More Efficient
3. Align Technology Executive to Present at Upcoming Financial Conferences
4. Pioneer Surgical Technology Hires Vice President of New Business Development
5. Purdue researchers develop technology to detect cancer by scanning surface veins
6. Creative Technology Services Enhances its Global Competitiveness with Additional Regulatory Certifications
7. University of Wisconsin Hospitals and Clinics Complete System-Wide Conversion to Masimo SET Pulse Oximetry Technology
8. Patent Reform Legislation Threatens Americas Leadership in Medical Technology Innovation
9. Stevens Health, Technology and Society roundtable: Sept. 19
10. Microbiotic technology developed for microinjection of zebrafish embryos
11. Proven Terumo Coronary Guidewire Technology Is Now Available in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)PEMBROKE, Bermuda, Dec. 4 Allied World Assurance,Company Holdings, Ltd (NYSE: AWH ) today announced that Scott Carmilani,President and Chief Executive Officer, and Jack Sennott, Executive Vice,Pres
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
(Date:12/4/2009)Late recurrence is a risk for some pediatric cancers, particularly Ewing sarcomas and tumors of the central nervous system, according to a new study published online December 4 in the Journal of the
(Date:12/4/2009)More than 15 million Americans are recruited annually to participate in clinical trials according to the Alliance for Human Research Protection (AHRP), and most will be compensated for their participa
(Date:12/4/2009)Increasing exercise, water and fruit consumption leads to success, study finds , , FRIDAY, Dec. 4 (HealthDay News) -- Increased exercise, reduced soda consumption and self-weighing are among
Breaking Medicine News(10 mins):Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:Human guinea pigs wary of high-paying medical trials 2Health News:Teens Lose More Weight Using Healthy Strategies 2
...enter Institute (JCVI) announced today that they h... from the National Institute of Allergy and Infect...utes of Health, as one of their Genomic Sequencing...nable JCVI to continue to expand its decades-long ...
...th Month and groups across the country and around ...n celebration of this awareness period. The purpo...ess of preventable health problems and encourage e...Father,s Day, a special awareness period recognize...
...a global leader in high-performance polymer extrus... International Sales. Gifford is experienced in ge...s development within the manufacturing, financial,... success record in terms of the sale of complex an...
...ability equates to success, , , FRIDAY, Ma...ive pitchers the extra edge they need to rule the ...lvic control of 24 pitchers, ages 18 to 26, in the...s wore a device that measured pelvic stability by ...
...s Expanding Ocular Pharmaceuticals Portfolio and O...cular Bacterial Pathogens(1) - , , , MADISON, N....ye health, today announced that the U.S. Food and ...eferred to as "pink eye." Besivance(TM) is a ne...
...vides Better Diagnosis and Treatment for Patients ...Kenneth L. Reed, M.D. performed the first revoluti...mpression (D.N.D.) procedure to treat acute and ...th area. The surgery is also currently being perfo...
Other Medicine News:Health News:J. Craig Venter Institute Awarded $43 Million, Five Year Contract From NIAID to Continue to Develop and Provide Sequencing, Genotyping, and Bioinformatics Expertise and Services in Infectious Diseases 2Health News:J. Craig Venter Institute Awarded $43 Million, Five Year Contract From NIAID to Continue to Develop and Provide Sequencing, Genotyping, and Bioinformatics Expertise and Services in Infectious Diseases 3Health News:Join Men's Health Network in Celebration of Men's Health Month 2Health News:Join Men's Health Network in Celebration of Men's Health Month 3Health News:Gifford Named Zeus Director of International Sales 2Health News:Pitching Prowess May Start With the Pelvis 2Health News:Bausch & Lomb Receives FDA Approval of Besivance(TM), New Topical Ophthalmic Antibacterial for the Treatment of Bacterial Conjunctivitis ('Pink Eye') 2Health News:Bausch & Lomb Receives FDA Approval of Besivance(TM), New Topical Ophthalmic Antibacterial for the Treatment of Bacterial Conjunctivitis ('Pink Eye') 3Health News:Bausch & Lomb Receives FDA Approval of Besivance(TM), New Topical Ophthalmic Antibacterial for the Treatment of Bacterial Conjunctivitis ('Pink Eye') 4Health News:Bausch & Lomb Receives FDA Approval of Besivance(TM), New Topical Ophthalmic Antibacterial for the Treatment of Bacterial Conjunctivitis ('Pink Eye') 5Health News:Kenneth L. Reed, M.D. Performs First State of the Art AccuraScope(TM) Procedure in Dallas 2
(Date:12/4/2009)ANNAPOLIS, Md., Dec. 4 PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, announced today the presentation of new d
(Date:12/4/2009)LAKE FOREST, Ill., Dec. 4 Hospira, Inc. (NYSE: HSP ), a leading global specialty pharmaceutical and medication delivery company, today announced the launch of its next-generation 50 mL and 100 mL V
(Date:12/4/2009)ANNAPOLIS, Md., Dec. 4 PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Company is prese
Breaking Medicine Technology:PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6Agito Networks Recognized in the 2009 Tech Innovators Awards Program by Everything Channel 62068 1Agito Networks Recognized in the 2009 Tech Innovators Awards Program by Everything Channel 62068 2Agito Networks Recognized in the 2009 Tech Innovators Awards Program by Everything Channel 62068 3Bionorica Offers Expert Resources Health Tips for Natural Moms 62064 1Bionorica Offers Expert Resources Health Tips for Natural Moms 62064 2Two Major Universities Join Nations Leading Postgrad Bio Job Board 14970 1Two Major Universities Join Nations Leading Postgrad Bio Job Board 14970 2
... Pharmasset, Inc.,(Nasdaq: VRUS ) announces that... clevudine for the treatment of chronic hepatitis ...sults of R7128 for the treatment of,chronic hepati...rs in Drug,Development in Viral Hepatitis (HEP-DAR...cember 9 - 13, 2007. The abstract titles and abbre...
... Magazines like Time, Newsweek,and U.S. World and ...,probiotics. Researchers have found compelling evi...t key to digestive and immune health, but Eastern,...f probiotics, found in,fermented foods such as yog...nning to tout probiotic benefits, Russian scientis...
Other Medicine Technology:Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART 2Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART 3Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART 4Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART 5Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART 6Are Muramyl Peptides the Magic Bullet in Probiotics? 2Are Muramyl Peptides the Magic Bullet in Probiotics? 3
New Image Cut-to-Fit Flextend Skin Barrier, Floating Flange
New Image Cut-to-Fit Convex Flextend Skin Barrier, with Tape
CenterPointLock Urostomy Pouch
CenterPointLock Sterile Urostomy Kit
Medicine Products: